Semaglutide Bests Exenatide in Type 2 Diabetes Semaglutide Bests Exenatide in Type 2 Diabetes

Subcutaneous injection of semaglutide provides superior results to exenatide extended release (ER), also administered subcutaneously, in patients who have diabetes inadequately controlled by oral agents, according to findings from an open-label trial.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news